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The platinum analog CI-973 was selected for clinical study because it is 
associated with fewer and milder toxicities than either cisplatin or 
carboplatin in experimental animals, and because it has activity against 
cisplatin-resistant cell lines in vitro.  In this Phase 2 study, 31 women 
with platinum-resistant or recurrent ovarian carcinoma were treated with 
CI-973. Three patients achieved a complete response, defined as the 
disappearance of all measurable disease. The median Kaplan-Meier 
survival time was estimated to be approximately 7 months from the start 
of treatment. The most frequently occurring drug-related toxicities were 
neutropenia, nausea, vomiting, asthenia, anemia, abdominal pain, and 
diarrhea. Most toxicities were mild or moderate and none resulted in 
withdrawal from treatment. Despite this favorable toxicity profile, the 
low response rate of 10% does not support further clinical development 
of CI-973 as treatment for ovarian cancer. 
KEYWORDS" CI-973, ovarian cancer, Phase 2 study, platinum analog. 
Ovarian cancer is the leading cause of gynecologic 
cancer deaths and the fourth leading cause of all cancer 
deaths among women in the USA (1"2). Because ovarian 
cancer is usually asymptomatic in its early stages, most 
patients have widespread disease at the time of 
diagnosis. The yearly mortality rate is currently 65% of 
the incidence rate, and the 5-year survival rate in 
patients with stage III or IV disease is less than 10%, 
despite aggressive surgery and chemotherapy. More 
than half ovarian cancer cases occur in women over 65 
years of age; therefore, the incidence of this disease will 
likely rise as the median age of the population increases. 
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Platinum analogs are one of the most widely used 
chemotherapeutic agents for the frontline treatment of 
ovarian cancer (B) . However, their effectiveness is often 
limited in recurrent disease because tumor cells 
develop resistance to further treatment. Cisplatin is 
associated with dose-limiting nephrotoxicity, neuro- 
toxicity, ototoxicity, and emetogenesis, making it difficult 
for many patients to tolerate adequate therapy (4). 
Carboplatin, which is the only other platinum-contain- 
ing compound approved for clinical use, is somewhat 
less toxic than cisplatin, but exhibits nearly complete 
cross-resistance with cisplatin both in vitro and clinically. 
CI-973 (NK121) is a third-generation, water-soluble 
cisplatin analog with antitumor activity superior 
or equivalent to cisplatin and carboplatin against 
cisplatin-resistant murine and human tumor cell lines 
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in vitro and in vivo (4-6). Phase I studies in patients with 
solid tumors  indicate that, unlike cisplatin, CI-973 does 
not appea r  to cause serious renal toxicity, neurotoxi- 
city, or ototoxicity (7-9). CI-973 is myelosuppress ive ,  
causing dose-l imiting neutropenia,  but  is not asso- 
ciated with the dose-limiting thrombocytopenia  char- 
acteristic of carboplat in therapy.  This multicenter 
Phase 2 s tudy  was  per formed to determine the clinical 
efficacy of CI-973 in patients with advanced ovarian 
carcinoma that has progressed  or recurred after 
t reatment  wi th  cisplatin or carboplatin,  and to further 
define the safety profile of this experimental  drug. 
Patients and methods 
Patients 
Thirty-one patients with histologically confirmed 
FIGO stage III or IV measurable  epithelial ovarian 
carcinoma were  enrolled in this study. This was a 
modera te ly  to heavily pretreated patient populat ion,  
which had  had one (15 patients) or two (14 patients) 
prior chemothe rapy  regimens for advanced  disease. 
All had received prior  cisplatin a n d / o r  carboplatin 
therapy,  and 84% were considered plat inum-resistant  
because they had  either failed to respond or had 
relapsed or progressed within 6 months  of complet ing 
prior  p la t inum-based  therapy (Table 1). Disease 
progression or recurrence was  documented  by  lapa- 
ro tomy,  paracentesis, CT scan, or physical examination 
Table 1. Patient characteristics 




Race, n (%) 
White 20 (65) 
Black 6 (19) 
Hispanic 4 (13) 
Asian 1 (3) 
Performance status, n (%) 
0 9 (29) 
1 2O (65) 
2 1 (3) 
Unknown 1 (3) 
Number of prior chemotherapy regimens, n (%) 
3 1 (3) 
2 14 (45) 
1 15 (48) 
Adjuvant only 1 (3) 
Disease status, n (%) 
Platinum-resistant 26 (84) 
Recurrent* 5 (16) 
*Recurred more than 6 months after completing prior platinum 
therapy. 
within one month  prior  to t reatment  with CI-973. 
Patients had not received chemotherapy  or radiation 
therapy for at least 4 weeks prior  to treatment.  Patients 
who  had received prior  intraperitoneal chemotherapy  
or abdominal  or pelvic radiation were  not eligible for 
t reatment  with CI-973. At baseline, patients had a 
creatinine clearance >1 mL sec-1,  an ALT level < twice 
the uppe r  limit of normal  of the institution, and a total 
bilirubin level < 34.2 ~tmol L - l .  Baseline hematologic 
criteria included an absolute granulocyte count of 
> 1.5 x 10 9 L 1 and platelet count of > 100 x 10  9 L -1. 
Measurements  of hematologic parameters  and blood 
chemistries were  per formed weekly dur ing treatment. 
Urinalysis, measurement  of serum CA125 levels, and 
creatinine clearance estimates were per formed every 3 
weeks. Monitoring for CI-973-related toxicity occurred 
throughout  the s tudy and an evaluation of toxicity 
occurred at the end of each treatment  period. Toxicities 
were  graded according to the National  Cancer 
Institute common  toxicity criteria. 
Drug administration 
CI-973 was  adminis tered as a 30-minute intravenous 
infusion once every 21 days. The starting dose was 
190 mg  m - 2 ,  which could be increased or decreased by  
25% for subsequent  doses, depending on each patient 's  
tolerance of therapy. Patients who  had progression 
were  wi thd rawn  from the study. Patients whose  best 
response to therapy was stable disease could receive 
up  to four courses of CI-973. Patients who  achieved a 
complete or partial  response to t reatment  received 
CI-973 until relapse or recurrence. 
Response  criteria 
Sentinel lesions were  measured  either by physical 
exam or CT scan at baseline and 3 weeks after each 
dose. Objective response was  determined by  compar-  
ing the size of measurable  sentinel lesions after at least 
one course of t reatment  to the size at baseline 
according to s tandard  criteria for the evaluation of 
solid tumors  (1°'11). A complete response (CR) was 
defined as the d isappearance  of all known  disease. A 
partial response (PR) was a 50% or greater  decrease in 
the sum of the product  of cross-sectional diameters  
( tumor size) of sentinel lesions and no appearance  of 
new lesions. Both complete  and partial responses had 
to be confirmed at least 3 weeks after the initial 
assessment  of response. Stable disease was defined as 
a less than 50% decrease and less than 25% increase in 
tumor  size, with no appearance  of new lesions. 
Progressive disease was  defined as a 50% or greater 
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increase in the size of any one sentinel lesion, or the 
appearance of a new lesion. Changes in CA125 levels 
were not included in definitions of response. 
Results 
Three of 31 patients (9.7%) responded to treatment 
(Table 2). One responder  had platinum-resistant 
disease. The patient was a 46-year old woman  who  
had previously achieved a partial response to 
treatment with cisplatin plus cyclophosphamide.  She 
achieved a CR on Day 67 after three courses of CI-973. 
She relapsed approximately 2 months  later on Day 130 
after having received a total of six courses of therapy. 
Her  CA125 level remained elevated throughout  
treatment with CI-973. Two responders had recurrent 
ovarian cancer that was not proven to be platinum- 
resistant. One such responder was a 44-year-old woman  
whose ovarian cancer had recurred approximately 4 years 
after she had received a regimen containing cisplatin, 
doxorubicin, and cyclophosphamide.  The patient 
achieved a CR on Day 88 after four courses of CI-973 
and her CA125 level normalized. She remained in CR 
through her sixth course of therapy (Day 170), then 
was lost to follow-up. The patient later developed 
recurrent disease and reinitiated therapy with CI-973 
on Day 585. The date of recurrence and thus the duration 
of response were unknown.  She did not respond to 
four additional courses of therapy and was wi thdrawn 
from the study on Day 742 because of progressive disease. 
The patient died of her disease on Day 881, approxi- 
mately 2.5 years after her first dose of CI-973. The 
second responder  with recurrent disease was a 67-year 
old woman  who had previously achieved a complete 
response to carboplatin plus cyclophosphamide.  The 
patient achieved a CR on Day 56 after two courses of 
CI-973 treatment and her CA125 level had normalized 
by  Day 77. She received a total of 18 courses of CI-973 
and has remained in CR for over one year (13.7 months). 
No treatment-related deaths occurred. At last 
contact, 13 patients had died of their ovarian cancer. 
The median Kaplan-Meier  survival time was esti- 
mated to be 224 days, or 7.4 months  (Fig. 1). 
Table 2. Rates of response to CI-973 therapy 
n (%) 
Complete response* 3 (9.7) 
Partial response 0 
Stable disease 17 (54.8) 
Progressive disease 11 (35.5) 
*By measurable disease criteria. Normal CA125 levels were not 
required. 
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Fig. 1. Kaplan-Meier survival curve; *, a censored patient. 
No patient was wi thdrawn from the s tudy because 
of treatment-related toxicity. Neutropenia was dose- 
limiting. The median nadir absolute neutrophil  count 
was 1.200 x 109 L -1 and the nadir occurred a median 
of 15 days after dosing. Filgrastim was used at the 
investigators' discretion. Fifteen patients (48%) experi- 
enced grade W neutropenia (<0.500 x 109 L-J) .  The 
median time to recovery (~>1.000x109 L -1) was 
7 days, with a range of 2-15 days. Two patients 
experienced treatment-associated febrile neutropenia,  
and one of these patients subsequently developed 
sepsis. Both patients recovered within 5 days. Three 
other grade IV adverse events occurred in one patient 
each (vomiting, headache, and anemia). These events 
were not considered treatment-related. 
The most frequently occurring CI-973-associated 
toxicities were neutropenia,  nausea a n d / o r  vomiting, 
asthenia, anemia, abdominal  pain, and diarrhea (Table 
3). Most of the occurrences were mild or moderate.  
Neurotoxicity was infrequent and consisted largely of 
mild, reversible paresthesias. One patient experienced 
intermittent tinnitus, which was considered possibly 
treatment-related even though it was present at 
baseline. There were no cases of nephrotoxicity. 
Discussion 
CI-973 was developed with the goal of obtaining an 
anticancer agent that was active against cisplatin- 
Table 3. Toxicities occurring in at least 20% of patients 
Toxicity n (%) 
Leukopenia 26 (84) 
Nausea and/or vomiting 25 (81) 
Asthenia 12 (39) 
Anemia 9 (29) 
Abdominal pain 8 (26) 
Diarrhea 8 (26) 
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resistant tumors and was not associated with the dose- 
limiting toxicities characteristic of cisplatin. Preclinical 
studies were promising: not only was the ant i tumor 
activity of CI-973 comparable to cisplatin and superior 
to carboplatin against cisplatin-sensitive tumor  cell 
lines, CI-973 also exhibited a high degree of activity 
against several cell lines that were highly cisplatin- 
resistant ~4-6~. Animal toxicology studies showed that 
dose-limiting toxicity primarily targeted the hemato- 
poietic system and gastrointestinal tract. Unlike 
cisplatin, CI-973 was not ototoxic and did not produce 
renal toxicity. There was also no evidence of 
neurotoxicity. Phase I studies in patients with solid 
tumors established that neutropenia was the dose- 
limiting toxicity, and confirmed that CI-973 was not 
seriously nephrotoxic, neurotoxic, or ototoxic (7-9). 
Furthermore, it did not cause severe thrombocytopenia, 
even in patients who developed Grade IV neutropenia. 
The results obtained in this Phase 2 s tudy have 
confirmed all of these previously reported data. 
The Phase 2 program was designed to determine the 
level of ant i tumor activity of CI-973 against a variety 
of solid tumors. Ovarian cancer was chosen as one of 
the tumor  types for s tudy because of its relative 
sensitivity to initial t reatment with plat inum com- 
pounds  and the problem of the development  of 
plat inum resistance ~3~. Given that CI-973 had in vitro 
activity against cisplatin-resistant cell lines, it was a 
promising candidate for the treatment of advanced 
ovarian cancer. However ,  the activity of CI-973 against 
advanced epithelial ovarian cancer in this s tudy was 
minimal: the observed response rate was only 10% (3/ 
31 patients) and in one patient the response was only 
of 2 months  duration. Furthermore,  two of the 
responses occurred among the group of five patients 
whose cancer was potentially platinum-sensitive. A 
response rate ~> 20% would have justified further 
s tudy of CI-973 in ovarian cancer. Although the 
observed response rate of 10% was not statistically 
different from a response rate of 20% (Z value = 1.17), 
the sample size of 31 patients provided only 47% 
power  to detect a difference of 10%. Therefore, these 
results do not support  the development  of CI-973 as 
single-agent therapy for this indication. In addition, 
they suggest that preclinical models of plat inum 
resistance may  not always correlate with clinical 
activity in patients with ovarian cancer. It may  be 
necessary to better define such models to enhance the 
prospect of identifying a plat inum analog with clinical 
activity in patients with refractory ovarian cancer. 
However ,  with its relatively mild toxicity profile, CI- 
973 may be a suitable candidate for inclusion in a dose 
intensification chemotherapy regimen. For example, 
the dose-limiting neutropenia was of brief duration 
and was rarely associated with infection. Therefore, 
concurrent  therapy with GCSF or GMCSF could be 
expected to overcome this toxicity and allow the use of 
higher, possibly more effective doses. 
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